curious how this impacts either approval or future earnings. I did see that the lack of effectiveness was a concern to approving it, which was EU's reason for turning down the approval of our drug. http://www.foxnews.com/health/2012/08/29/fda-backs-use-humira-to-treat-ulcerative-colitis/
FDA will rule on this indication by year end. The panel results were given, so far, but article says FDA has to decide, still.
Humira is not that effective according to reasons for previously failing to gain UC labeling; and FDA didn't approve it yet. This was an ADCOM vote. Humira is pretty heavy duty and expensive compared to the Uceris and drugs like Lialda / Asacol.